Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
Add more filters










Publication year range
5.
J Med Chem ; 52(19): 5785-8, 2009 Oct 08.
Article in English | MEDLINE | ID: mdl-19743867

ABSTRACT

We report the synthesis and SAR of a series of novel azaindole CB(2) agonists. 6-Azaindole 18 showed activity in an acute pain model but was inactive in a chronic model. 18 is a Pgp substrate with low brain penetration. The template was redesigned, and the resulting 5-azaindole 36 was a potent CB(2) agonist with high CNS penetration. This compound was efficacious in the acute model and the chronic joint pain model.


Subject(s)
Aminopyridines/therapeutic use , Brain/metabolism , Morpholines/therapeutic use , Pain/drug therapy , Receptor, Cannabinoid, CB2/agonists , Aminopyridines/pharmacokinetics , Animals , Aza Compounds , CHO Cells , Cell Line , Chronic Disease , Cricetinae , Cricetulus , Drug Discovery , Humans , Indoles , Morpholines/pharmacokinetics , Rats , Structure-Activity Relationship
6.
J Orofac Pain ; 23(3): 265-74, 2009.
Article in English | MEDLINE | ID: mdl-19639106

ABSTRACT

AIMS: To investigate the presence of proteinase-activated receptor 2 (PAR2) in the human tooth pulp and to determine whether there are any changes in receptor expression with caries and pain. METHODS: Forty-four mandibular first permanent molars were collected from children (n = 36, mean age 9.96 years +/- 2.11) requiring dental extractions under general anesthesia. Teeth were categorized as either intact (n = 22) or carious (n = 22). Carious teeth were further subdivided into asymptomatic (n = 10) and painful (n = 12). The coronal pulp was removed and processed for indirect immunofluorescence by using antibodies raised against PAR2 and double labeled with either a neuronal marker (protein gene product 9.5) or both a smooth muscle cell (aSMA) and endothelial (UEIL) marker, in order to examine PAR2 presence in both neuronal and vascular tissue. In addition, hemotoxylin and eosin staining was performed to identify pulpal fibroblasts. RESULTS: PAR2 expression was found to be present in pulpal nerve fibers, vascular tissue, and pulpal fibroblasts. PAR2 neuronal expression was not affected by the presence of caries (P > .05) but was significantly less in carious painful teeth than in carious asymptomatic teeth (P < .05). No changes in vascular PAR2 expression were found (P > .05); however, the number of PAR2-labeled fibroblast-like cells per mm2 was significantly greater in carious teeth (P < .05). CONCLUSION: These findings indicate that PAR2 receptors and changes in their level of expression may have relevance and clinical importance in nociception.


Subject(s)
Dental Caries/metabolism , Dental Pulp/metabolism , Receptor, PAR-2/biosynthesis , Toothache/metabolism , Child , Dental Pulp/blood supply , Dental Pulp/cytology , Dental Pulp/innervation , Fibroblasts/metabolism , Fluorescent Antibody Technique, Indirect , Humans , Microvessels/metabolism , Molar , Nerve Fibers/metabolism
7.
Bioorg Med Chem Lett ; 19(15): 4504-8, 2009 Aug 01.
Article in English | MEDLINE | ID: mdl-19520573

ABSTRACT

A novel series of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidine-based cyclooxygenase-2 (COX-2) inhibitors, which have a different arrangement of substituents compared to the more common 1,2-diarylheterocycle based molecules, have been discovered. For example, 2-(butyloxy)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (47), a member of the 2-pyrimidinyl ether series, has been shown to be a potent and selective inhibitor with a favourable pharmacokinetic profile, high brain penetration and good efficacy in rat models of hypersensitivity.


Subject(s)
Amines/chemical synthesis , Cyclooxygenase 2 Inhibitors/chemical synthesis , Ethers/chemical synthesis , Pyrimidines/chemical synthesis , Sulfones/chemical synthesis , Amines/pharmacology , Animals , Brain/drug effects , Brain/metabolism , Chemistry, Pharmaceutical/methods , Cyclooxygenase 2/chemistry , Cyclooxygenase 2 Inhibitors/pharmacology , Disease Models, Animal , Drug Design , Ethers/pharmacology , Humans , Inflammation , Inhibitory Concentration 50 , Mice , Molecular Structure , Neurodegenerative Diseases/drug therapy , Pyrimidines/pharmacology , Rats , Sulfones/pharmacology
8.
Bioorg Med Chem Lett ; 19(1): 259-63, 2009 Jan 01.
Article in English | MEDLINE | ID: mdl-19010671

ABSTRACT

We describe herein the medicinal chemistry approach which led to the discovery of a novel pyridine-3-carboxamide series of CB(2) receptor agonists. The SAR of this new template was evaluated and culminated in the identification of analogue 14a which demonstrated efficacy in an in vivo model of inflammatory pain.


Subject(s)
Analgesics/chemical synthesis , Pyridines/chemical synthesis , Pyridines/therapeutic use , Receptor, Cannabinoid, CB2/agonists , Amides/chemical synthesis , Amides/pharmacology , Amides/therapeutic use , Analgesia/methods , Animals , Disease Models, Animal , Drug Discovery/methods , Inflammation , Pain/drug therapy , Pyridines/pharmacology , Structure-Activity Relationship
11.
Neurosci Lett ; 441(1): 110-4, 2008 Aug 15.
Article in English | MEDLINE | ID: mdl-18597934

ABSTRACT

We have investigated a possible role for the ATP receptor subunit P2X(3), in the development of neuropathic pain following injury to a peripheral branch of the trigeminal nerve. In nine anaesthetised adult ferrets the left lingual nerve was sectioned and recovery permitted for 3 days, 3 weeks or 3 months (3 ferrets per group). A retrograde tracer, fluorogold, was applied to the nerve to allow identification of cell bodies in the trigeminal ganglion with axons in the injured nerve. Indirect immunofluorescence for P2X(3) and image analysis was used to quantify the percentage area of staining at the site of injury. Additionally, the proportion of fluorogold-positive cells that expressed P2X(3) was determined and compared with expression in non-fluorogold containing cells in another part of the ganglion. Comparisons were made with results from control animals that only received the tracer injection. After lingual nerve injury there was no significant change in P2X(3) expression at the site of nerve injury or within cell bodies linked to either injured (lingual) or uninjured (ophthalmic) axons, at any of the time periods investigated. Overall, this study suggests that P2X(3) expression at these sites is not involved in the development of neuropathic pain following lingual nerve injury.


Subject(s)
Lingual Nerve Injuries , Lingual Nerve/metabolism , Receptors, Purinergic P2/metabolism , Animals , Female , Ferrets , Functional Laterality , Receptors, Purinergic P2X3 , Recovery of Function/physiology , Stilbamidines , Time Factors
12.
Neurosci Lett ; 443(1): 41-5, 2008 Sep 26.
Article in English | MEDLINE | ID: mdl-18634850

ABSTRACT

Abnormal neural activity generated at a site of nerve injury is thought to contribute to the development of dysaesthesia. Vanilloid receptor 1 (TRPV1), a transducer of noxious stimuli, may be involved in the initiation of this abnormal activity and could provide a useful therapeutic target. We investigated the effect of a specific TRPV1 antagonist (SB-750364) on injury-induced discharge in the lingual nerve. In 12 anaesthetised adult ferrets the left lingual nerve was sectioned and animals were allowed to recover for 3-7 days. In terminal experiments under general anaesthesia, the nerve was re-exposed and electrophysiological recordings made from spontaneously active axons in fine filaments dissected from the nerve central to both the injury site and the junction with the chorda tympani. SB-750364 was infused via the cephalic vein in order to achieve three increasing but stable systemic blood levels of the compound (0.3, 1.0 and 3.0 microM). Twenty-eight spontaneously active units were studied, with discharge frequencies ranging from 0.02 to 4.9 Hz. There was a significant reduction in spontaneous activity in 17 units (61%) at 1.0 microM or less of SB-750364 (p<0.01; Friedman test with Dunn's multiple comparisons). A further 4 units (14%) showed a significant reduction in activity at 3.0 microM (p<0.01). In the remaining 7 units (25%) the discharge was unaffected (p>0.05). These data show that the TRPV1 antagonist SB-750364 can reduce the level of spontaneous activity initiated in some axons following lingual nerve injury.


Subject(s)
Cranial Nerve Injuries , Lingual Nerve/drug effects , TRPV Cation Channels/antagonists & inhibitors , Action Potentials/drug effects , Animals , Cranial Nerve Injuries/drug therapy , Cranial Nerve Injuries/pathology , Cranial Nerve Injuries/physiopathology , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Ferrets , Lingual Nerve/physiopathology , Lingual Nerve Injuries , Male , Neural Conduction/drug effects , Neural Conduction/physiology , Physical Stimulation , TRPV Cation Channels/metabolism
13.
J Pain ; 9(7): 580-7, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18420461

ABSTRACT

UNLABELLED: The role of specific nicotinic receptor (nAChR) subtypes in antinociception has not been fully elucidated because of the lack, until recently, of selective tool compounds. (R)-N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiopene-2-carboxamide) (compound B) is reported to be an agonist selective for the alpha(7)nAChR and in the present study was found to be efficacious in inflammatory pain models in 2 species. Compound B reversed complete Freund adjuvant-induced reductions in paw withdrawal thresholds in rat and mouse in a dose-related manner, producing maximum reversals of 65% +/- 4% at 10 mg/kg and 87% +/- 15% at 20 mg/kg. When rats and mice were predosed with the centrally penetrant, broad-spectrum nicotinic receptor antagonist mecamylamine, the efficacy of the agonist was significantly inhibited, producing reversals of only 11% +/- 5% at 10 mg/kg and 5% +/- 13% at 20 mg/kg, confirming activity via nicotinic receptors. Rats were also predosed systemically with the selective low-brain penetrant alpha(7)-antagonist methyllycaconitine, which had no effect on agonist activity (90% +/- 18% at 10 mg/kg), suggesting a central involvement. This hypothesis was further established with methyllycaconitine completely inhibited the agonist effect when dosed intrathecally (1% +/- 7%). PERSPECTIVE: These studies provide good rationale for the utility of selective, central nervous system penetrant agonists at the alpha(7)-nicotinic receptor for the treatment of inflammatory pain.


Subject(s)
Benzofurans/pharmacology , Hyperalgesia/drug therapy , Quinuclidines/pharmacology , Receptors, Nicotinic/physiology , Aconitine/administration & dosage , Aconitine/analogs & derivatives , Aconitine/pharmacology , Animals , Behavior, Animal/drug effects , Benzofurans/administration & dosage , Dose-Response Relationship, Drug , Female , Freund's Adjuvant , Hyperalgesia/chemically induced , Hyperalgesia/physiopathology , Inflammation/chemically induced , Inflammation/metabolism , Inflammation/physiopathology , Injections, Intraperitoneal , Male , Mecamylamine/administration & dosage , Mecamylamine/pharmacology , Mice , Mice, Inbred C57BL , Models, Animal , Nicotinic Antagonists/administration & dosage , Nicotinic Antagonists/pharmacology , Pain/drug therapy , Pain/metabolism , Pain/physiopathology , Pain Measurement/methods , Quinuclidines/administration & dosage , Rats , Weight-Bearing/physiology , alpha7 Nicotinic Acetylcholine Receptor
14.
Eur J Pain ; 12(3): 385-94, 2008 Apr.
Article in English | MEDLINE | ID: mdl-17897851

ABSTRACT

We have developed a model to study central changes following inflammation of the tooth pulp in the ferret and have examined Fos expression in the trigeminal nucleus following stimulation of non-inflamed and inflamed tooth pulps. The aim of this study was to establish the ability of this model to predict analgesic efficacy in clinical studies of inflammatory pain. We addressed this by assessing the effects of the neurokinin-1 receptor antagonist GR205171A and ibuprofen on Fos expression following stimulation of the inflamed pulp and comparing this with known analgesic efficacy. Adult ferrets were prepared under anaesthesia to allow tooth pulp stimulation, recording from the digastric muscle and intravenous injections at a subsequent experiment. In some animals pulpal inflammation was induced, by introducing human caries into a deep buccal cavity. After 5 days, animals were reanaesthetised, treated with vehicle, GR205171A or ibuprofen and the teeth were stimulated at ten times the threshold of the jaw-opening reflex. Stimulation of all tooth pulps induced ipsilateral Fos in trigeminal subnuclei caudalis and oralis. GR205171A had no significant effect on Fos expression in the trigeminal nucleus of animals with either non-inflamed or inflamed tooth pulps. Ibuprofen reduced Fos expression in the trigeminal nucleus and this effect was most marked in animals with pulpal inflammation. These results differ from those previously described using a range of other animal models, but agree with known clinical efficacy of neurokinin-1 receptor antagonists and ibuprofen. Therefore this model is likely to be of use in accurately predicting the analgesic efficacy of novel compounds.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Dental Pulp/innervation , Gene Expression Regulation/drug effects , Genes, fos/drug effects , Ibuprofen/pharmacology , Nerve Tissue Proteins/biosynthesis , Neurokinin-1 Receptor Antagonists , Peptide Fragments/pharmacology , Proto-Oncogene Proteins c-fos/biosynthesis , Pulpitis/physiopathology , Substance P/analogs & derivatives , Trigeminal Nuclei/metabolism , Animals , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Cuspid , Cyclooxygenase Inhibitors/pharmacology , Cyclooxygenase Inhibitors/therapeutic use , Drug Evaluation, Preclinical , Electric Stimulation , Ferrets , Ibuprofen/therapeutic use , Nerve Tissue Proteins/genetics , Peptide Fragments/therapeutic use , Pulpitis/drug therapy , Pulpitis/genetics , Receptors, Neurokinin-1/physiology , Substance P/pharmacology , Substance P/therapeutic use , Trigeminal Neuralgia/drug therapy , Trigeminal Neuralgia/etiology , Trigeminal Neuralgia/physiopathology , Trigeminal Nuclei/physiopathology
15.
J Med Chem ; 50(11): 2597-600, 2007 May 31.
Article in English | MEDLINE | ID: mdl-17477516

ABSTRACT

Selective CB2 receptor agonists are promising potential therapeutic agents for the treatment of inflammatory and neuropathic pain. A focused screen identified a pyrimidine ester as a partial agonist at the CB2 receptor with micromolar potency. Subsequent lead optimization identified 35, GW842166X, as the optimal compound in the series. 35 has an oral ED50 of 0.1 mg/kg in the rat FCA model of inflammatory pain and was selected as a clinical candidate for this indication.


Subject(s)
Analgesics/chemical synthesis , Pain/drug therapy , Pyrans/chemical synthesis , Pyrimidines/chemical synthesis , Receptor, Cannabinoid, CB2/agonists , Analgesics/pharmacokinetics , Analgesics/pharmacology , Animals , Biological Availability , Half-Life , Humans , Inflammation/drug therapy , Inflammation/metabolism , Pain/metabolism , Pyrans/pharmacokinetics , Pyrans/pharmacology , Pyrimidines/pharmacokinetics , Pyrimidines/pharmacology , Rats , Structure-Activity Relationship
16.
Eur J Oral Sci ; 115(1): 40-7, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17305715

ABSTRACT

We have previously carried out detailed characterization and identification of Fos expression within the trigeminal nucleus after tooth pulp stimulation in ferrets. The aim of this study was to determine the effect of pulpal inflammation on the excitability of central trigeminal neurons following tooth pulp stimulation. Adult ferrets were prepared under anesthesia to allow tooth pulp stimulation, recording from the digastric muscle, and intravenous injections at a subsequent experiment. In some animals, pulpal inflammation was induced by introducing human caries into a deep buccal cavity. After 5 d, animals were re-anaethetized, and the teeth were stimulated at 10 times the threshold of the jaw-opening reflex. Stimulation of all tooth pulps induced ipsilateral Fos in the trigeminal subnuclei caudalis and oralis. All non-stimulated animals showed negligible Fos labeling, with no differences recorded between inflamed and non-inflamed groups. Following tooth pulp stimulation, Fos expression was greater in animals with inflamed teeth than in animals with non-inflamed teeth, with the greatest effect seen in the subnucleus caudalis. These results suggest that inflammation increases the number of trigeminal brainstem neurons activated by tooth pulp stimulation; this may be mediated by peripheral or central mechanisms.


Subject(s)
Proto-Oncogene Proteins c-fos/biosynthesis , Pulpitis/physiopathology , Trigeminal Nucleus, Spinal/metabolism , Animals , Dental Caries/complications , Dental Pulp/innervation , Electric Stimulation , Ferrets , Gene Expression , Pulpitis/etiology
17.
Eur J Pain ; 11(2): 192-201, 2007 Feb.
Article in English | MEDLINE | ID: mdl-16542859

ABSTRACT

We have investigated a possible role for vanilloid receptor 1 (TRPV1), a transducer of noxious stimuli, in the development of neuropathic pain following injury to a peripheral branch of the trigeminal nerve. In nine adult ferrets the left lingual nerve was sectioned and recovery permitted for 3 days, 3 weeks or 3 months (3 ferrets per group). A retrograde tracer, fluorogold, was injected into the damaged nerve to identify associated cell bodies in the trigeminal ganglion. Three further ferrets, receiving only tracer injection, served as uninjured controls. Indirect immunofluorescence for TRPV1 and image analysis was used to quantify the percentage area of staining (PAS) of TRPV1 in the left and right lingual nerves. Additionally, the proportion of fluorogold positive and fluorogold negative cells expressing TRPV1 in the ganglion was determined. TRPV1 expression increased significantly at the injury site of damaged nerves 3 days after injury and this was matched by a reduction in the proportion of fluorogold positive cells expressing TRPV1 in the ganglion. At 3 weeks TRPV1 expression at the injury site was still high, while in the ganglion was significantly greater than in the controls. In the 3-month recovery group TRPV1 expression in both nerve fibres and ganglion cells, was not significantly different from controls and there were no changes in expression in the fluorogold negative cells in the ganglion at any time point studied. These data suggest that after injury there is an increase in the axonal transport of TRPV1 from the cell bodies to the damaged axons and this is followed by an increase in synthesis in the ganglion. These changes in expression may be involved in development of sensory disturbances or dysaesthesia after injury.


Subject(s)
Lingual Nerve Injuries , Lingual Nerve/metabolism , Neuralgia/metabolism , TRPV Cation Channels/metabolism , Trigeminal Ganglion/metabolism , Animals , Female , Ferrets , Fluorescent Antibody Technique, Indirect , Fluorescent Dyes , Stilbamidines
18.
Brain Res ; 1127(1): 59-65, 2007 Jan 05.
Article in English | MEDLINE | ID: mdl-17109831

ABSTRACT

The lingual nerve, a peripheral branch of the trigeminal nerve, can be damaged during the surgical removal of lower third molar teeth. This damage can lead to the development of dysaesthesia, with some patients complaining of burning pain. We investigated the hypothesis that vanilloid receptor 1 (TRPV1), a transducer of noxious heat stimuli, was involved in the development of this burning pain. Neuroma specimens were obtained from patients undergoing microsurgical repair of a damaged lingual nerve. Repair was undertaken where there was little evidence of spontaneous recovery, 7-41 months after the initial injury. Preoperatively the incidence of dysaesthesia was determined by reported symptoms and using visual analogue scales (VAS) for pain, tingling and discomfort. Nine neuromas were studied from patients with burning dysaesthesia and six from patients with a sensory deficit but no dysaesthesia. Indirect immunofluorescence for protein gene product (PGP) 9.5 and TRPV1 was used to quantify the percentage area of PGP 9.5 positive neuronal tissue that also expressed TRPV1. The results showed no significant difference between the mean percentage area of TRPV1 expression in neuromas from patients with or without burning dysaesthesia. Furthermore, there was no correlation between TRPV1 expression and the VAS scores for pain, tingling or discomfort. However, if data from all patients was pooled, there was a negative correlation between the level of TRPV1 expression and the time after initial injury. These data do not rule out involvement of TRPV1 in the aetiology of burning dysaesthesia following lingual nerve injury but suggest that TRPV1 at the injury site does not play a primary role.


Subject(s)
Lingual Nerve Injuries , Lingual Nerve/metabolism , Neuralgia/metabolism , Neuroma/metabolism , TRPV Cation Channels/metabolism , Trigeminal Nerve Diseases/metabolism , Adult , Chronic Disease , Female , Humans , Lingual Nerve/physiopathology , Male , Middle Aged , Molar, Third/anatomy & histology , Neuralgia/etiology , Neuralgia/physiopathology , Neuroma/etiology , Neuroma/physiopathology , Nociceptors/metabolism , Oral Surgical Procedures/adverse effects , Pain, Intractable/etiology , Pain, Intractable/metabolism , Pain, Intractable/physiopathology , Paresthesia/etiology , Paresthesia/metabolism , Paresthesia/physiopathology , Postoperative Complications/etiology , Postoperative Complications/physiopathology , Trigeminal Nerve Diseases/etiology , Trigeminal Nerve Diseases/physiopathology
20.
Exp Neurol ; 202(1): 207-16, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16908020

ABSTRACT

We have investigated the expression of TTX-sensitive (TTXs) and TTX-resistant (TTXr) sodium channel subtypes following injury to the inferior alveolar nerve (IAN), in order to determine their potential role in the development of trigeminal neuropathic pain. In seven anaesthetised ferrets, fluorogold (2%) was injected into the left IAN to identify cell bodies with axons in this nerve. In four animals, the nerve was sectioned distal to the injection site and the remaining three served as controls. After 3 days, the animals were perfused with 4% paraformaldehyde. The left and right IANs and trigeminal ganglia were processed using indirect immunofluorescence with specific primary antibodies to TTXs subtypes Na(v)1.3 and Na(v)1.7 and TTXr subtypes Na(v)1.8 and Na(v)1.9. Image analysis was used to quantify the percentage area of staining (PAS) in the nerves. In the ganglia, counts were made of positively labelled cells in the fluorogold population. PAS for Na(v)1.8 and Na(v)1.9 was significantly greater in injured nerves than in either contralateral or control nerves. After injury, significantly fewer cells in the ganglia expressed Na(v)1.3 (controls 36.9%; injured 13.1%), Na(v)1.7 (controls 17.0%; injured 8.1%) and Na(v)1.9 (controls 60.3%; injured 29.0%) (p<0.05, unpaired t test). These changes are different from those previously reported in the dorsal root ganglion following damage to peripheral nerves of spinal origin. As they occur at a time of known high abnormal neural discharge, it seems likely that changes in sodium channel expression may play a role in nerve injury-induced trigeminal pain.


Subject(s)
Gene Expression Regulation/physiology , Sodium Channels/metabolism , Trigeminal Nerve Diseases/physiopathology , Animals , Ferrets , Immunohistochemistry/methods , Mandibular Nerve/metabolism , Mandibular Nerve/pathology , Sodium Channels/classification , Trigeminal Ganglion/metabolism , Trigeminal Nerve Diseases/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...